Tango Therapeutics, Inc.
TNGX
$10.08
-$0.34-3.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M |
| Cost of Revenue | 30.82M | 32.81M | 36.44M | 33.94M | 33.26M |
| Gross Profit | 23.00M | -29.63M | -31.05M | -29.82M | -21.66M |
| SG&A Expenses | 8.92M | 11.34M | 11.48M | 11.09M | 11.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.74M | 44.15M | 47.92M | 45.03M | 44.49M |
| Operating Income | 14.07M | -40.97M | -42.53M | -40.91M | -32.88M |
| Income Before Tax | 15.87M | -38.82M | -39.84M | -37.62M | -29.11M |
| Income Tax Expenses | -10.00K | 35.00K | 34.00K | 49.00K | 54.00K |
| Earnings from Continuing Operations | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.88M | -38.85M | -39.88M | -37.67M | -29.17M |
| EBIT | 14.07M | -40.97M | -42.53M | -40.91M | -32.88M |
| EBITDA | 14.63M | -40.34M | -41.91M | -40.29M | -32.26M |
| EPS Basic | 0.14 | -0.35 | -0.36 | -0.35 | -0.27 |
| Normalized Basic EPS | 0.09 | -0.22 | -0.23 | -0.19 | -0.17 |
| EPS Diluted | 0.13 | -0.35 | -0.36 | -0.35 | -0.27 |
| Normalized Diluted EPS | 0.08 | -0.22 | -0.23 | -0.19 | -0.17 |
| Average Basic Shares Outstanding | 110.97M | 110.54M | 110.30M | 108.68M | 108.51M |
| Average Diluted Shares Outstanding | 117.78M | 110.54M | 110.30M | 108.68M | 108.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |